A cost-effective model for preliminary site evaluation for the reintroduction of a threatened quillwort

Cost-effectiveness of new treatments for

Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model

✍ Gisela Kobelt; Linus Jönsson; Anders Mattiasson 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Economic analyses of interventions for chronic diseases require evaluations over a long timeframe to illustrate the benefits and costs of treatments. Clinical trials are generally short and carried out in strictly controlled conditions. They are therefore of limited value for economic evaluation aim